Financials Evome Medical Technologies Inc.
Equities
BRTL
CA30053H1055
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.12 CAD | 0.00% | +50.00% | -42.86% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 5.272 | 5.501 | 5.506 | 29.53 | 24.78 | 16.46 |
Enterprise Value (EV) 1 | -0.77 | -3.803 | -2.844 | 22.45 | 35.61 | 40.23 |
P/E ratio | -0.64 x | -6.01 x | -2.28 x | -8 x | -1.29 x | -0.99 x |
Yield | 4.81% | - | - | - | - | - |
Capitalization / Revenue | -1.91 x | 1.78 x | -271 x | -880 x | 0.63 x | 0.27 x |
EV / Revenue | 0.28 x | -1.23 x | 140 x | -669 x | 0.9 x | 0.67 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | 0.48 x | 0.49 x | 0.61 x | 3.26 x | 1.68 x | 4.19 x |
Nbr of stocks (in thousands) | 33,785 | 33,785 | 33,813 | 46,146 | 55,063 | 78,370 |
Reference price 2 | 0.1560 | 0.1628 | 0.1628 | 0.6400 | 0.4500 | 0.2100 |
Announcement Date | 7/3/18 | 6/28/19 | 6/25/20 | 4/30/21 | 4/3/23 | 4/16/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | -2.754 | 3.085 | -0.0203 | -0.0335 | 39.61 | 59.99 |
EBITDA | - | - | - | - | - | - |
EBIT | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -7.924 | -0.7606 | -1.768 | -2.667 | -22.84 | -15.55 |
Net income 1 | -8.06 | -0.7606 | -2.341 | -2.667 | -19.08 | -15.6 |
Net margin | 292.65% | -24.65% | 11,517.83% | 7,951.3% | -48.16% | -26.01% |
EPS 2 | -0.2442 | -0.0271 | -0.0713 | -0.0800 | -0.3478 | -0.2124 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share 2 | 0.007500 | - | - | - | - | - |
Announcement Date | 7/3/18 | 6/28/19 | 6/25/20 | 4/30/21 | 4/3/23 | 4/16/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: |
---|
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 10.8 | 23.8 |
Net Cash position 1 | 6.04 | 9.3 | 8.35 | 7.08 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | -52.5% | -6.42% | -17.5% | -33.1% | -44.2% | -161% |
ROA (Net income/ Total Assets) | -47.1% | -6.22% | -16.9% | -23.3% | -15.7% | -31.1% |
Assets 1 | 17.12 | 12.22 | 13.88 | 11.43 | 121.8 | 50.15 |
Book Value Per Share 2 | 0.3300 | 0.3300 | 0.2700 | 0.2000 | 0.2700 | 0.0500 |
Cash Flow per Share 2 | 0.1800 | 0.2800 | 0.2500 | 0.2100 | 0.0300 | 0.0100 |
Capex 1 | 0.01 | - | - | - | 0.77 | 0.2 |
Capex / Sales | -0.27% | - | - | - | 1.94% | 0.34% |
Announcement Date | 7/3/18 | 6/28/19 | 6/25/20 | 4/30/21 | 4/3/23 | 4/16/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.86% | 7.09M | |
+3.26% | 209B | |
+6.55% | 183B | |
+31.66% | 158B | |
+34.32% | 114B | |
+5.13% | 67.29B | |
+19.33% | 54.83B | |
-3.30% | 46.88B | |
-4.84% | 38.58B | |
+3.83% | 36.65B |
- Stock Market
- Equities
- BRTL Stock
- Financials Evome Medical Technologies Inc.